STOCKS TELEGRAPH

Tag: Equillium Inc

  • Did Anything Boost Equillium (EQ) Stock Premarket Today?

    Equillium Inc. (EQ) shares gained 4.61% to $5.90 in premarket trading today. Equillium stock gained 1.81% to finish the last trading session at $5.64. Trading volume for the EQ stock was 0.18 million shares, which is higher than the 0.14 million daily average volume published over the past 50 days.

    In the last five days, EQ stock price has risen -1.91%, but in the last month, it has dropped -19.20%. This year, the price of EQ stock has gained 76.80 percent so far after losing -14.29 percent over the last three months. EQ’s stock rose after it announced plans to initiate a pivotal study.

    EQ’s study was about what?

    Biotechnology company Equillium is developing novel products for severe autoimmune and inflammatory disorders, which have high demands for treatment. It leverages its deep understanding of immunobiology to identify and develop products. In addition to the planned pivotal study in acute graft-versus-host disease (aGVHD), EQ is also testing itolizumab in lupus/lupus nephritis and asthma.

    The US Food and Drug Administration (FDA) and Equillium have completed an End-of-Phase 1 meeting for itolizumab for the treatment of acute graft-versus-host disease (aGVHD), as announced by the company in a press release yesterday.

    • EQ and the FDA confirmed progress on Phase 3 pivotal study of itolizumab in aGVHD in preparation for the Biologics License Application (BLA) submission.
    • EQ plans to begin its Phase 3 study in the fourth quarter of 2021.
    • Due to the positive outcome of its FDA meeting, EQ will immediately begin a pivotal clinical trial, taking it one step closer to obtaining FDA approval for the first-line treatment of aGVHD.
    • Current standard of care, high-dose corticosteroids, falls significantly short of the needs of this severely ill patient population.
    • Clinical responses from Equillium’s EQUATE Phase 1b were rapid and durable, and a rapid abatement in systemic corticosteroid use was shown to be vital for positive long-term outcomes.
    • EQ has received FDA fast track and orphan drug designations for itolizumab, and with the FDA’s feedback, the company is immediately moving to late-stage development and will focus on collecting data necessary for submission of a BLA.

    How will EQ proceed with the study?

    Equillium (EQ) received FDA guidance on how to design the pivotal study at this meeting. Equillium also received guidance from the FDA on chemistry, manufacturing, and controls (CMC), nonclinical, and regulatory issues to support its proposed study and BLA submission of itolizumab for the first line treatment of aGVHD in combination with corticosteroids. As a result of FDA feedback and guidance, Equillium (EQ) is finalizing the details of its Phase 3 protocol.

  • What changed for these 49 stocks in Pre-Market Session?

    What changed for these 49 stocks in Pre-Market Session?

    Fuel Tech Inc. (FTEK) stock plunged -8.8% to $1.14 in the pre-market trading after the technology company offered advanced engineering solutions for the optimization of combustion, pollution control, and water treatment systems in utility and industrial applications, financial results for the third quarter were officially published. The most recent rating by H.C. Wainwright, on March 13, 2020, is at a Neutral.

    Equillium Inc. (NASDAQ: EQ) shares are trading down -4.17% at $4.83 at the time of writing after on November 11, the company announced quarterly results for the third quarter of 2020. The company’s 52-week range was noted as $2.20 to $27.05. Analysts have a consensus price target of $24.

    Immuron Limited (IMRN) tumbled over -4.17% at $8.05 in pre-market trading today. US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine.

    Infinity Pharmaceuticals Inc. (INFI), a Biotechnology company, dropped about -6.62% at $1.41 in pre-market trading Thursday following an earnings surprise of -6.67 percent was revealed by the company. It was anticipated a quarter ago that this drugmaker would report a loss of $0.20 per share when it actually posted a $0.16 loss, providing a 20 percent surprise.
    .

    Tellurian Inc. (TELL) stock moved down -5.6 percent to $1.18 in the pre-market trading following the company finished the third quarter of 2020, with cash and cash equivalents of roughly $77.9 million and current borrowings of about $80.8 million. The balance sheet of Tellurian accounted for about $293.3 million in total assets.

    Co-Diagnostics Inc. (CODX) gained over 5.19% at $13.99 in pre-market trading Thursday 12 November 2020. Co-Diagnostics, Inc. CoPrimers™ Shown to be Effective in COVID-19 Saliva PCR Tests Without Sample Extraction.

    Abeona Therapeutics Inc. (ABEO) is down more than -3.85% at $1.25 in pre-market hours Thursday 12 November 2020 after a front-runner in gene and cell therapy, revealed quarterly results and business updates. The stock had jumped over 13.04% to $1.30 in the last trading session.

    Before the trading started on 12 November 2020, MannKind Corporation (MNKD) is down -3.57% to reach $2.7. It has been trading in a 52-week range of $0.80 to $2.52.

    RAVE Restaurant Group Inc. (RAVE) stock plunged -11.84% to $0.67 in the pre-market trading. The most recent rating by ROTH Capital, on May 12, 2016, is at a Neutral.

    Dada Nexus Limited (NASDAQ: DADA) shares are trading up 5.08% at $32.7 at the time of writing. The company’s 52-week range was noted as $14.60 to $37.38. Analysts have a consensus price target of $36.

    FuelCell Energy Inc. (FCEL) tumbled over -1.49% at $2.65 in pre-market trading today.

    Zoom Video Communications Inc. (ZM), a Telecom Services company, rose about 3.38% at $427.3 in pre-market trading Thursday.

    Canaan Inc. (CAN) stock moved up 3.05 percent to $2.7 in the pre-market trading.

    Muscle Maker Inc. (GRIL) lost over -9.6% at $1.79 in pre-market trading Thursday 12 November 2020.

    Moderna Inc. (MRNA) is up more than 5.03% at $86.59 in pre-market hours Thursday 12 November 2020. The stock had jumped over 8.40% to $82.44 in the last trading session. Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273).

    Before the trading started on 12 November 2020, Coty Inc. (COTY) is down -3.89% to reach $4.45 after the company topped analysts’ outlook and surged as much as 22.2% on Nov 6 following its first-quarter fiscal 2021 results. It has been trading in a 52-week range of $2.65 to $13.01.

    Pinduoduo Inc. (PDD) stock soared 17.53% to $131.0 in the pre-market trading following an innovative and emerging tech firm and one of the top Chinese e-commerce players, revealed its unaudited financial results for the third quarter ended September 30, 2020. The most recent rating by Goldman, on November 03, 2020, is a Buy.

    Sea Limited (NYSE: SE) shares are trading up 3.48% at $175.01 at the time of writing following the news recently that pharmaceutical companies are closing on their COVID-19 vaccine candidates. The company’s 52-week range was noted as $30.50 to $187.75. Analysts have a consensus price target of $164.

    GrowGeneration Corp. (GRWG) grew over 7.26% at $22.46 in pre-market trading today after GrowGeneration reported record third-quarter 2020 Financial Results.

    Blink Charging Co. (BLNK), a Specialty Retail company, rose about 5.09% at $10.73 in pre-market trading Thursday.

    LightInTheBox Holding Co. Ltd. (LITB) stock moved up 3.31 percent to $2.5 in the pre-market trading.

    Bionano Genomics Inc. (BNGO) gained over 14.13% at $0.639 in pre-market trading Thursday 12 November 2020. Multi-Center Evaluation of Bionano Optical Genome Mapping by Cytogenetics Thought Leaders in the US Leads to Recommendation for Bionano’s Saphyr to Replace Karyotyping as First-Line Test for Detection and Identification of Structural and Copy Number Variants in Leukemia Patients.

    Vroom Inc. (VRM) is down more than -9.88% at $36.77 in pre-market hours Thursday 12 November 2020 following Vroom reported third Quarter 2020 results. The stock had jumped over 6.56% to $40.80 in the last trading session.

    Before the trading started on 12 November 2020, Turkcell Iletisim Hizmetleri A.S. (TKC) is up 3.16% to reach $5.23. It has been trading in a 52-week range of $4.36 to $6.36.

    Himax Technologies Inc. (HIMX) stock soared 12.2% to $4.6 in the pre-market trading after the prediction of Revenue to surge by approx. 10% consecutively and Gross Margin to get close to 29%. The most recent rating by Credit Suisse, on April 01, 2020, is at an Outperform.

    Qualigen Therapeutics Inc. (NASDAQ: QLGN) shares are trading down -10.03% at $3.23 at the time of writing. The company’s 52-week range was noted as $3.29 to $21.50.

    NovaBay Pharmaceuticals Inc. (NBY) grew over 8.82% at $0.67 in pre-market trading today.

    IMAC Holdings Inc. (IMAC), a Medical Care Facilities company, rose about 146.1% at $2.05 in pre-market trading Thursday. IMAC Holdings, Inc. Expands Missouri Footprint with Acquisition of Lockwood Chiropractic in Webster Groves.

    Sino-Global Shipping America Ltd. (SINO) stock moved up 62.18 percent to $3.13 in the pre-market trading.

    InVivo Therapeutics Holdings Corp. (NVIV) lost over -3.21% at $0.555 in pre-market trading Thursday 12 November 2020.

    Castor Maritime Inc. (CTRM) is up more than 18.5% at $0.1595 in pre-market hours Thursday 12 November 2020 after the company posted fiscal Results for the Three Months and Nine Months Ended September 30, 2020. The stock had jumped over 4.95% to $0.13 in the last trading session.

    Before the trading started on 12 November 2020, Just Energy Group Inc. (JE) is down -13.28% to reach $5.29 as a retail energy provider specializing in electricity and natural gas commodities, revealed its quarterly results for the fiscal year 2021. It has been trading in a 52-week range of $4.27 to $93.72.

    OraSure Technologies Inc. (OSUR) stock soared 4.55% to $14.02 in pre-market trading after the company recently topped its 3rd quarter fiscal earnings predictions. The most recent rating by Evercore ISI, on August 21, 2020, is at an Outperform.

    Riot Blockchain Inc. (NASDAQ: RIOT) shares are trading up 4.17% at $3.75 at the time of writing after the news that Bitcoin might take off again after a big gap. The company’s 52-week range was noted as $0.51 to $4.58.

    NortonLifeLock Inc. (NLOK) tumbled over -7.02% at $18.68 in pre-market trading today despite the earnings beat in the recent week.

    NIO Limited (NIO), an Auto Manufacturers company, rose about 3.41% at $44.55 in pre-market trading Thursday after the analyst’s prediction that NIO can be the main player in the Electric Vehicle market.

    JD.com Inc. (JD) stock moved up 5.38 percent to $87.3 in the pre-market trading following the news that JD.com was the largest US seller in China on Singles day.

    Kandi Technologies Group Inc. (KNDI) gained over 8.84% at $6.77 in pre-market trading Thursday 12 November 2020 despite its disappointing sales results in the financial 3rd quarter of this year.

    ICL Group Ltd (ICL) is up more than 3.11% at $3.98 in pre-market hours Thursday 12 November 2020 as the company topped analysts’ outlook on every front. The stock had jumped over 3.21% to $3.86 in the last trading session.

    Before the trading started on 12 November 2020, Uxin Limited (UXIN) is down -3.81% to reach $1.01 after the news that the company’s proprietary rating system has been introduced that assesses and determines the quality of a used vehicle, offers greater precision to make the decision-making process simpler for consumers and enhances the overall consumer experience. The stock has been trading in a 52-week range of $0.72 to $3.30.

    Baozun Inc. (BZUN) stock soared 3.07% to $40.57 in pre-market trading after the news that the stock still carries a great potential for investors. The most recent rating by Credit Suisse, on June 03, 2020, is at an Outperform.

    XpresSpa Group Inc. (NASDAQ: XSPA) shares are trading up 4.47% at $1.87 at the time of writing after the news that the firm to offer Business Update and will reveal Third Quarter 2020 Financial Results on November 16, 2020. The company’s 52-week range was noted as $0.15 to $8.82.

    KE Holdings Inc. (BEKE) grew over 3.48% at $72.02 in pre-market trading today after the news that the company will announce its quarterly report on November 16, 2020.

    Revolve Group Inc. (RVLV), an Internet Retail company, dropped about -8.96% at $20.43 in pre-market trading Thursday after the company Announced Third Quarter 2020 Financial Results with topping all analysts predictions.
    .

    American Tower Corporation (REIT) (AMT) stock moved up 2.75 percent to $245.0 in the pre-market trading after the reports that the company took over InSite Wireless Group for USD 3.5 billion.

    BIO-key International Inc. (BKYI) gained over 16.2% at $0.52 in pre-market trading Thursday 12 November 2020.

    Liminal BioSciences Inc. (LMNL) is up more than 11.19% at $4.57 in pre-market hours Thursday 12 November 2020 after the report that the firm will reschedule its announcement of quarterly results and conference call. The stock had jumped over 2.49% to $4.11 in the last trading session.

    Before the trading started on 12 November 2020, GoHealth Inc. (GOCO) is down -4.5% to reach $12.73. It has been trading in a 52-week range of $10.02 to $26.25.

    XPeng Inc. (XPEV) stock soared 10.53% to $37.06 in pre-market trading after the company unveiled upbeat quarterly results. The most recent rating by Citigroup, on November 04, 2020, is a Buy.

  • 18 Biotech Stocks That Are Great Options To Invest In

    18 Biotech Stocks That Are Great Options To Invest In

    The biotech industry is considered to be an attractive industry for the investor. This industry is continuously adopting new technological advancements. As time passes by every aspect of daily existence experience changes because of new technological breakthroughs and advancement in knowledge. Technology plays an important role in changing the lifestyle of humans. This technology also plays a very important role in the biotech industry.

    This technology has historically grown quickly. The biotech industry is striving to develop a treatment for complex diseases. It is anticipated that in 2021, one of the continuing trends in biotech is the continued improvement and development of drug research. The new technology help researchers to improve and assess diagnosis and treatment using medications.

    Check out the top 18 biotech companies you should add to your portfolio:

    BioLineRx Ltd. (NASDAQ: BLRX)

    BioLineRx Ltd. (NASDAQ: BLRX) shares were trading up 33.78% at $1.98 at the time of writing on Friday. BioLineRx Ltd. (NASDAQ: BLRX) share price went from a low point around $1.06 to briefly over $3.04 in the past 52 weeks, though shares have since pulled back to $1.98. BLRX market cap has remained high, hitting $39.57M at the time of writing. BioLineRx Ltd. (BLRX) has earlier announced the promising results from the ongoing GENESIS Phase III trial motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.

    Miragen Therapeutics Inc. (NASDAQ: MGEN)

    Miragen Therapeutics Inc. (NASDAQ: MGEN) last closed at $1.31, in a 52-week range of $0.31 to $2.27. Miragen Therapeutics Inc. (MGEN) has earlier acquired  Viridian Therapeutics, Inc. It has traded up 321.22% and traded down -42.29% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 4.80 and a quick ratio of 4.80. This company has a market capitalization of $79.29 million at the time of writing.

    Equillium Inc. (NASDAQ: EQ)

    Equillium Inc. (NASDAQ: EQ) stock soar by 5.83% to $6.35. The most recent rating by H.C. Wainwright, on July 14, 2020, is at a Buy. Previously, Equillium Inc. (EQ) has revealed that it has received a ‘Study May Proceed letter’ from the U.S. Food and Drug Administration (FDA) to commence a Phase 3 clinical trial, titled  EQUINOX, evaluating itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).

    Titan Pharmaceuticals Inc. (NASDAQ: TTNP)

    Titan Pharmaceuticals Inc. (NASDAQ: TTNP) shares headed falling, lower as much as -3.24%. The most recent rating by Maxim Group, on June 26, 2019, is at a Buy. Titan Pharmaceuticals Inc. (TTNP) revealed the pricing of an underwritten public offering of 80,000,000 units at a price of $0.10 per unit. Each unit issued in the offering comprised of one share of common stock and one warrant to purchase one share of common stock.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) rose 2.34% after gaining more than $0.06 on Friday. Trevena Inc. (TRVN) has disclosed that oliceridine has been classified as a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA). Looking at its liquidity, it has a current ratio of 16.20 and a quick ratio of 16.20. This company has a market capitalization of $381.29 million at the time of writing.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) last closed at $6.94, in a 52-week range of $1.45 to $19.39. Sorrento Therapeutics Inc. (SRNE) has earlier announced preclinical data about intravenous COVI-AMG™ (STI-2020; Affinity Matured COVI-GUARD) neutralizing antibody (nAb) in a preprint publication.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) shares headed falling, lower as much as -1.69%. The most recent rating by Alliance Global Partners, on June 26, 2020, is at a Buy. iBio Inc. (IBIO) has earlier appointed Dr. Alexandra Kropotova to its Board of Directors, effective as of October 14, 2020. Dr. Kropotova has also been chosen as a member of iBio’s new Science & Technology Committee, which shall be chaired by Dr. Philip Russell.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) fall -6.10% after losing more than -$0.64 on Friday. Inovio Pharmaceuticals Inc. (INO) announced that it is scheduled to release its third-quarter financial results of 2020 on November 9, 2020.  This company has a market capitalization of $1.76 billion at the time of writing.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) last closed at $4.92, in a 52-week range of $0.27 to $17.49. A class action has started on behalf of certain shareholders in Vaxart, Inc. It has traded up 1749.62% and traded down -71.87% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 4.00 and a quick ratio of 4.00. This company has a market capitalization of $580.22 million at the time of writing.

    Axovant Gene Therapies Ltd. (NASDAQ: AXGT)

    Axovant Gene Therapies Ltd. (NASDAQ: AXGT) stock drop by -41.64% to $2.13. The most recent rating by Cantor Fitzgerald, on April 17, 2020, is at an Overweight. Axovant Gene Therapies Ltd. (AXGT) has earlier announced program updates on Friday, October 30, 2020, at 11:30 AM Eastern time, for the Company’s AXO-Lenti-PD gene therapy for Parkinson’s disease.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) shares headed falling, lower as much as -2.20%. The most recent rating by Needham, on November 14, 2019, is at a Buy. Akebia Therapeutics Inc. (AKBA) earlier revealed that it is scheduled to announce its financial results for the third quarter ended September 30, 2020, on November 5, 2020, before the opening of the market.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) fall -5.35% after losing more than -$3.81 on Friday. Moderna Inc. (MRNA) earlier revealed that it has been recognized as one of the global biopharmaceutical industry’s top employers in Science and ScienceCareers’ 2020 Top Employers Survey for the sixth consecutive year.

    Heat Biologics Inc. (NASDAQ: HTBX)

    Heat Biologics Inc. (NASDAQ: HTBX) stock soar by 3.45% to $1.20. The most recent rating by B. Riley Securities, on October 14, 2020, is at a Buy. Heat Biologics Inc. (HTBX) share price went from a low point around $0.19 to briefly over $4.30 in the past 52 weeks, though shares have since pulled back to $1.20. HTBX market cap has remained high, hitting $172.30 Million at the time of writing.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) last closed at $0.26, in a 52-week range of $0.10 to $1.56. Onconova Therapeutics Inc. (ONTX) revealed that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) stock drop by -4.27% to $4.93. The most recent rating by H.C. Wainwright, on May 18, 2020, is at a Buy. Clovis Oncology Inc. (CLVS) is scheduled to release its third-quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX)

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares headed rising, higher as much as 2.41%. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight. BioCryst Pharmaceuticals Inc. (BCRX) revealed that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).

    Soligenix Inc. (NASDAQ: SNGX)

    Soligenix Inc. (NASDAQ: SNGX) rose 0.59% after gaining more than $0.01 on Friday. Soligenix Inc. (SNGX) has disclosed that continued optional treatment with SGX301 across all lesions during the compassionate use, safety portion of the trial (Cycle 3), for a total of 6 months in the study, continued to significantly improve responses and remained safe and well-tolerated in its FLASH study.

    Scholar Rock Holding Corporation (SRRK)

    Scholar Rock Holding Corporation (SRRK) last closed at $38.90, in a 52-week range of $6.95 to $46.50. Analysts have a consensus price target of $30.00. Scholar Rock Holding Corporation (SRRK) announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share.

  • Equillium (NASDAQ: EQ) Gets FDA Green Signal To Start Phase 3 COVID-19 Trial

    Equillium (NASDAQ: EQ) Gets FDA Green Signal To Start Phase 3 COVID-19 Trial

    Shares of Equillium, Inc. (NASDAQ: EQ) soared 28.50% in the pre-trading hours after the company announced that it has got the ‘Study May Proceed Letter’ from the US Food and Drug Administration (FDA). After receiving a green signal from the FDA biotechnology company is planning to commence the COVID-19 Phase III trial, titled EQUINOX.

    In the EQUINOX Phase III trial, the company will officially enroll a total of 800 patients in the fourth quarter of 2020. FDA has also specified that the promising result of the study will also support the regulatory filing of a Biologic License Application (BLA).

    Equilium, Inc. (NASDAQ: EQ) shares were trading up 33.00% at $7.93 at the time of writing on Friday. It has a trading volume of 2.02 million in the pre-market trading session on Friday. Equilium, Inc. (EQ) share price went from a low point of around $2.20 to briefly over $27.05 in the past 52 weeks. It has moved up 172.73% from its 52-weeks low and moved down -77.82% from its 52-weeks high. EQ  market cap has remained high, hitting $144.84 million at the time of writing.

    Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. It is used to treat COVID-19 patients suffering from Acute Respiratory Distress Syndrome (ADS). Itolizumab has the ability to control cytokine cascade that is the basis of multiple complications in COVID-19 Patients. Patients have experienced various complications such as organ failure, blood clots, and tissue damage.

    COVID-19 is continuously spreading all over the world and has infected many patients all around the globe.  Equillium is striving to provide treatment to COVID-19 patients. In the Phase III trial, patients will get either placebo or Itolizumab and they will get up to two doses of either placebo or Itolizumab on Day 1 and Day 8 if necessary.

    All the patients will be closely monitored through Day 28 while hospitalized or through post-discharge follow-up. The main purpose of this study is to evaluate the benefits of itolizumab. The trial will also analyze the safety, tolerability, and pharmacokinetics (PK) of itolizumab.